Methods of reducing mammographic breast density and/or breast cancer risk
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10588912-B2
Publication Date
2020-03-17
Expiration Date
Abstract
The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.
Core Innovation
The disclosed invention provides a method of treating mammographic breast density (MBD) by administering an androgenic agent, namely testosterone, together with an aromatase inhibitor, namely anastrozole. The method further induces breast involution of breast cells in the patient. The disclosure addresses treatment and/or prevention of high mammographic breast density.
The disclosed approach also targets breast stiffness (BS) alongside mammographic breast density. It is described as expected to reduce MBD and reduce breast stiffness by inducing extracellular matrix degradation. The intended net biological effect is net cell death over proliferation during the treatment course.
The disclosure frames high mammographic breast density and breast stiffness as associated with breast cancer risk. It states that treatment can reduce breast cancer risk, including interval breast cancer risk, and can improve imaging/visualization including mammography and digital mammography/tomosynthesis (DBT). The disclosure further states potential benefits related to reduced breast compression pain and potentially less radiation exposure.
Claims Coverage
The partial content includes one independent claim. The inventive features center on co-administering testosterone with anastrozole to treat mammographic breast density and inducing breast involution of breast cells.
Co-administration of testosterone and anastrozole to treat MBD
Administering an effective amount of androgenic agent, namely testosterone, and an effective amount of an aromatase inhibitor, namely anastrozole.
Inducing breast involution of breast cells
Inducing breast involution of breast cells in the patient.
Across the independent claim, the core inventive concept is co-administration of testosterone and anastrozole to treat mammographic breast density, with induction of breast involution of breast cells.
Stated Advantages
Reduces mammographic breast density (MBD).
Reduces breast stiffness (BS).
Induces breast involution of breast cells.
Provides extracellular matrix degradation.
Reduces breast cancer risk, including interval breast cancer risk.
Improves imaging/visualization, including mammography and digital mammography/tomosynthesis (DBT).
Potentially reduces breast compression pain.
Potentially reduces radiation exposure.
Documented Applications
Treating mammographic breast density in a patient in need thereof by administering testosterone and anastrozole to induce breast involution.
Treating and/or preventing high mammographic breast density (MBD) and/or breast stiffness (BS) in pre-, peri-, and post-menopausal warm-blooded animals/humans.
Interested in licensing this patent?